PDF
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Oslo, Norway, 24 August 2023 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA and immunotherapy medicines, today announces its first half 2023 results.
Members of Circio's executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).
FIRST HALF 2023 HIGHLIGHTS
Corporate- The company was rebranded as Circio, an innovator in next generation circular RNA therapeutics
- A convertible bond facility with Atlas Special Opportunities was established, securing up to NOK 300 million in financing over three years
- The organization was restructured to reflect the new strategic focus on circRNA, which will lead to significant payroll savings
- Technical proof-of-concept was established for novel circVec vector types and designs, including demonstrating 15X extended half-life vs. mRNA in vitro
- A patent application was filed for the circAde concept
- Two circRNA posters were presented at the major oncology and gene therapy conferences AACR and ASGCT
- The first patient was dosed with TG01 in the multiple myeloma study at Oslo University Hospital
- The first patient was dosed with TG01 in the anti-PD-1 combination study in pancreatic cancer at Kansas University, USA
Erik Digman Wiklund, CEO commented: "Circular RNA is a powerful new format for RNA therapeutics, and with our differentiated circVec platform we have a unique opportunity to take a leading role in this emerging space. We are rapidly building our technical capabilities to demonstrate the versatility and broad potential of our technology and put Circio in position to capture the significant potential of vector-delivered circRNA."
Key figures
Amounts in NOK thousands 1H 2023 1H 2022 FY 2022
Total operating revenues 10 002
Total operating expenses -72 519 -59 786 -503 593
Operating profit/loss -72 519 -59 786 -493 591
Net financial items -3 443 164 -1 737
Income tax - 21 62 430
Net profit/loss -75 962 -59 601 -432 898
Basic and diluted EPS (NOK/share) -0.40 -0.32 -2.30
Net change in cash -34 652 -55 884 -115 667
Cash and cash equivalents start of period 66 015 181 682 181 682
Cash and cash equivalents end of period 31 363 125 798 66 015
The interim financial information has not been subject to audit
Presentation
We invite to a live webcast today at 10.00 CET. You can join the webcast here (https://bit.ly/3OCZMgI). It will be possible to submit questions during the presentation.
Reporting material- CRNA 1H'23 report.pdf (https://mb.cision.com/Public/17093/3822745/9e78cf10547768c8.pdf)
- CRNA 1H'23 presentation.pdf (https://mb.cision.com/Public/17093/3822745/a506c6d00da96250.pdf)
The half year report and presentation are also available at the website www.circio.com.
***